Dow Jones 30 Stocks SEC Filings — March 02, 2026

02-03-2026

Venture Global reported record FY 2025 revenue of $13.8B, up 177% YoY, with Consolidated Adjusted EBITDA of $6.3B (+198% YoY), driven by 380 LNG cargos exported (+170% YoY) and strong Plaquemines commissioning; Q4 revenue reached $4.4B (+192% YoY) and EBITDA $2.0B (+191% YoY). However, net income growth was slower at 53% YoY to $2.3B for FY and 23% YoY to $1.1B for Q4, due to lower LNG sales prices net of feed gas at Calcasieu, unfavorable interest rate swaps, and higher interest expense. The company announced new SPAs totaling ~9.75 MTPA, financings including $3.0B notes and $2.0B revolver, and 2026 EBITDA guidance of $5.2B-$5.8B amid expected 486-527 cargos.

• ·Expects 145-156 cargos from Calcasieu and 341-371 from Plaquemines in 2026.
• ·Plaquemines Phase I COD targeted Q4 2026; CP2 Phase II FID H1 2026.
• ·Hanwha SPA: 1.5 MTPA for 20 years starting 2030; Trafigura: 0.5 MTPA for 5 years from 2026.
• ·Prepaid $3.2B construction term loan with $3.0B notes proceeds.
• ·Q1 2026 EBITDA guidance $1.15B-$1.25B impacted by Winter Storm Fern and margin compression.

02-03-2026

Climb Global Solutions, Inc. (CLMB) filed an 8-K on March 2, 2026, under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits). The filing incorporates a press release dated March 2, 2026, as Exhibit 99.1. It was signed by Matthew Sullivan, Chief Financial Officer; no specific financial metrics, performance data, or event details are disclosed in the provided content.

02-03-2026

Archer Aviation reported record year-end liquidity of ~$2B for Q4 & FY 2025, positioning the company to fund certification, manufacturing scale-up, and commercial launches. Key milestones include 100% FAA Means of Compliance acceptance for Midnight aircraft, enabling progress toward Type Inspection Authorization (TIA) in 2026, expanded Midnight fleet for piloted VTOL ops in eIPP and UAE targeting first passenger flights in 2026, and new defense opportunities with Anduril including hybrid aircraft and powertrain sales. The order book is valued in the billions based on indicative $5M per aircraft pricing, with partnerships from PIF, Korean Air, Japan Airlines, and others.

• ·Midnight flight tests achieved over 50 miles, 30+ minutes flight time, altitudes above 10,000 feet, speeds of 150 mph
• ·Piloted VTOL campaign underway with newest Midnight aircraft; targeting piloted transition flight in coming months
• ·First third-party powertrain deal announced in November 2025 with Anduril and EDGE Group
• ·Submitted eIPP applications in California, Florida, Texas, Georgia, New York
• ·Hot weather flight testing initiated in Abu Dhabi in 2025

02-03-2026

First Bancorp announced that Michael G. Mayer retired as President of the Company and Chief Executive Officer of First Bank effective February 28, 2026, as part of its succession plan. Mr. Mayer will continue serving as a director on the Boards of Directors of both the Company and First Bank. The 8-K filing was signed by Richard H. Moore, Chief Executive Officer, on March 2, 2026.

02-03-2026

Coca-Cola Europacific Partners plc filed notifications of multiple PDMR transactions on February 19 and 26, 2026, including significant sales by executives Clare Wardle (12,000 Ordinary Shares for $1.26M) and Veronique Vuillod (1,416 Ordinary Shares for $0.15M), which may signal personal profit-taking. However, several executives including CFO Edward Walker, Chief Commercial Officer Stephen Lusk, and others acquired small fractional shares (around 3-4 shares each) under the UK Share Plan at an average of $57.53 and additional shares via RSU vesting or Shareshop, reflecting routine compensation alignments. All transactions occurred on Nasdaq.

• ·All transactions priced around USD $104.94-$105.48 per share for sales; acquisitions include $0.00 volumes for dividend equivalents or vesting.
• ·Company LEI: 549300LTH67W4GWMRF57.
• ·Gareth McGeown transaction on 2026-02-26; all others on 2026-02-19.

02-03-2026

On February 26, 2026, Erinn Thomas-Mackey resigned from the Board of Directors of Inspire Veterinary Partners, Inc. (IVP), effective immediately, with no disagreement on the company's operations, policies, or practices. The Form 8-K was filed on March 2, 2026, and signed by Kimball Carr, President and Chief Executive Officer.

• ·Company CIK: 0001939365
• ·EIN: 85-4359258
• ·State of Incorporation: Nevada
• ·Trading Symbol: IVP (Common stock, par value $0.0001)

02-03-2026

Purebase Corporation (PUBC) entered into an unsecured $1M line of credit agreement with affiliate CORETER LLC on February 27, 2026, at 8% annual interest, maturing one year later on February 27, 2027. Lender may convert outstanding principal and interest into common stock at maturity based on the weighted average closing price of the prior 20 trading days. Proceeds are designated for payroll, unpaid invoices, and operating expenses; the agreement is unsecured with no immediate advances specified.

• ·Loan advances require 3 business days written notice and are at Lender's sole discretion.
• ·Unsecured obligations; no registration rights for the Note or potential Conversion Shares under Securities Act.
• ·Related-party transaction as CORETER LLC is an affiliate of Borrower.

02-03-2026

DBV Technologies presented additional positive data from the successful Phase 3 VITESSE study at the AAAAI 2026 Annual Meeting, highlighting that 82.8% of children aged 4-7 treated with the VIASKIN Peanut Patch increased their eliciting dose by at least one step at month 12 versus 48% in placebo, and 60.1% increased by at least two steps versus 23.4%. The primary endpoint was met with 46.6% treatment responders versus 14.8% placebo (difference 31.8%), confirmed by sensitivity analyses (22.1%-27.8% above prespecified 15% threshold); however, 6.4% of treated subjects decreased their dose versus 24% on placebo. The patch was well-tolerated, and DBV plans a Biologics License Application submission to FDA in H1 2026.

• ·All sensitivity analyses statistically significant with 95% CI exceeding 15% threshold (22.1%-27.8%).
• ·Responder definition: baseline ED ≤30mg achieving ≥300mg at month 12, or baseline ED=100mg achieving ≥600mg.
• ·Subgroup deltas: baseline ED ≤30mg (∆34.6%, 95% CI 24.93-44.24); baseline ED=100mg (∆28.5%, 95% CI 17.51-39.5).
• ·Presentation available on DBV’s website Scientific Publications & Presentations page.
• ·BLA submission to FDA planned for first half of 2026.

02-03-2026

Lumexa Imaging reported preliminary unaudited Q4 2025 consolidated revenues of at least $261M, up from $248M YoY, and FY 2025 revenues of at least $1.016B, up from $948.9M, with Adjusted EBITDA growing to at least $63M in Q4 (from $53.7M) and $229M for the year (from $200.8M). However, Q4 net loss was roughly flat at approximately $25.4M (vs. $25.1M YoY), while FY net loss improved to $43.8M from $94.1M; consolidated total procedures grew 10.1% YoY in Q4 but system-wide total procedures rose only 3.4% for the FY. The company issued 2026 guidance for consolidated revenues of $1.045-1.097B and Adjusted EBITDA of $234-242M, opened 9 de novo centers in 2025, and highlighted PET volume growth of 17% consolidated.

• ·Completed IPO, reduced leverage, and refinanced debt in Q4 2025.
• ·Opened 3 wholly owned de novo centers and acquired 1 site in Q4 2025.
• ·Earnings call scheduled for March 26, 2026 at 8:30 a.m. ET.
• ·Presentations at Raymond James (March 2), Leerink (March 9), and Barclays (March 10) conferences.
• ·2026 guidance includes ~$7M public company costs, lowering implied EBITDA growth to 4% at midpoint.

02-03-2026

Norwegian Cruise Line Holdings reported FY2025 total revenue growth of 3.7% to $9.8B and Adjusted EBITDA up 11% to $2.73B exceeding guidance, with Adjusted EPS rising 19% to $2.11; however, GAAP net income declined sharply to $423.2M from $910.3M. Q4 2025 revenue increased 6% to $2.2B and Adjusted EBITDA grew 20% to $564M, but 2026 guidance projects flat full-year Net Yield on Constant Currency basis and a Q1 decline of ~1.6% due to Caribbean capacity absorption challenges and execution missteps. Net Leverage stood at 5.3x with $14.6B total debt, targeting ~5.2x by year-end 2026.

• ·New ship orders: three vessels (one per brand) for delivery in 2036 and 2037.
• ·FY2026 Adjusted Net Cruise Cost excluding Fuel per Capacity Day guidance: up ~0.9% Constant Currency vs 2025.
• ·Fuel expense Q4 2025: $168M, price per metric ton net of hedges $662 (up from $641 in 2024).
• ·Newbuild-and-Growth CapEx FY2025: $2.6B gross ($1.0B net of financing); FY2026 guidance: ~$2.8B gross (~$1.2B net).
• ·Oceania Sonata bookings surpassed Oceania Allura by 45% on launch day; debuts August 2027 with 1,390 guests capacity.
• ·Net Leverage target: ~5.2x by end-2026.

02-03-2026

Warner Bros. Discovery, Inc. (WBD) entered into a Merger Agreement on February 27, 2026, with Paramount Skydance Corporation (PSKY) and its subsidiary Prince Sub Inc., under which Merger Sub will merge with WBD, with WBD surviving as a wholly owned subsidiary of PSKY. WBD shareholders will receive $31.00 per share in cash, plus ticking consideration of $0.00277778 per day if closing after September 30, 2026 (capped at $0.25 per 90-day period). The boards of both companies unanimously approved the deal, which includes detailed treatments for vested/unvested equity awards and potential payments up to $1.528B related to certain senior notes.

• ·Vested WBD Options and RSUs convert to cash based on Merger Consideration excess over exercise price.
• ·Unvested equity awards assumed by PSKY with continued vesting terms; performance RSUs based on actual or extrapolated performance.
• ·PSKY standstill until Effective Time, June 4, 2027, or termination, prohibiting alternative transactions.
• ·PSKY may make Specified Request on WBD senior notes by October 15, 2026, or WBD may act thereafter.

02-03-2026

Yum China Holdings, Inc. filed an 8-K on March 2, 2026, under Item 7.01 Regulation FD Disclosure, announcing the issuance of its annual results for the year ended December 31, 2025, on February 27, 2026, in compliance with The Stock Exchange of Hong Kong Limited listing rules. The full announcement is available at https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0301/2026030100009.pdf. No specific financial metrics or period-over-period comparisons are provided in the filing itself.

• ·Securities registered: Common Stock, par value $0.01 per share (YUMC on NYSE; 9987 on HKEX)
• ·Principal executive offices: Yum China Building, 20 Tian Yao Qiao Road, Shanghai 200030, People’s Republic of China; 101 East Park Boulevard, Suite 805, Plano, Texas 75074, United States of America

02-03-2026

Kosmos Energy reported Q4 2025 net production of ~67,900 boepd, up ~4% QoQ, with revenues of $295 million, but posted a net loss of $377 million ($0.79/share) including $144 million write-off and $178 million impairments, with adjusted net loss of $78 million ($0.16/share). Year-end 1P reserves stood at ~250 mmboe (10-year life, 90% replacement ratio) and 2P at ~500 mmboe (20-year life, -18% replacement), bolstered by Ghana license extensions to 2040, while FY capex of $292 million was 25% below guidance. Key post-quarter moves included a $350 million bond offering, redemption of 2026 notes, TEN FPSO acquisition for opex savings, and sale of Equatorial Guinea assets for up to $220 million to accelerate debt reduction from $3.0 billion net debt.

• ·GTA production: Dec 2025 ~2.7 mtpa equivalent, 2026 YTD ~2.9 mtpa; Q4 net ~14,200 boepd.
• ·Jubilee: Current gross >70,000 bopd; J74 well ~13,000 bopd; J75 ~40m net pay, online Q1 2026 end.
• ·Equatorial Guinea sale details: Upfront $180M (adj.), contingents $12.5M (performance) + $9M/yr 2027-2029 (oil price/prod thresholds); effective Jan 1, 2025, close mid-2026.
• ·Hedges: 2026 8.5M bbl floor ~$66/bbl; 2027 2.0M bbl floor ~$60/bbl.
• ·Liquidity at Dec 31, 2025: $92M cash, $150M RBL undrawn, $100M Term Facility undrawn.
• ·Overhead reductions FY 2025: >$25M.
• ·FY 2026 capex guidance: ~$350M (~2/3 to Jubilee drilling).

02-03-2026

Bandwidth Inc. repurchased $100M aggregate principal of its 0.50% Convertible Senior Notes due 2028 at a discount to par via privately negotiated agreements, reducing outstanding principal from $250M to $150M, with closing expected on March 4, 2026. Simultaneously, its 0.25% Convertible Senior Notes due 2026 matured on March 1, 2026, and were fully retired with cash on hand, simplifying the capital structure and eliminating nearer-term maturities. The moves support a balanced capital allocation including an $80M share repurchase program, backed by record Q4 2025 profitability and expectations for 16% revenue growth and nearly 30% Adjusted EBITDA growth in 2026.

• ·Repurchases conducted via separate, privately negotiated agreements with a limited number of holders
• ·Repurchases payable in cash at a discount to par value
• ·Capped call transactions related to 2028 Notes expected to remain in effect

02-03-2026

Biglari Holdings Inc. reported full-year 2025 pre-tax operating earnings of $18.8M, a 42% decline from $32.6M in 2024, while Q4 operating earnings shifted to a $1.7M loss from a $3.9M profit. Investment losses widened sharply to $66.5M for the year from $40.7M, contributing to a net loss of $37.5M attributable to shareholders versus $3.8M in 2024. The 2025 Annual Report and 10-K are available at www.biglariholdings.com.

• ·Q4 2025 investment losses: -$62.3M vs -$21.9M in Q4 2024.
• ·Businesses include property and casualty insurance and reinsurance, licensing and media, restaurants, and oil and gas.
• ·Press release issued February 28, 2026; 2025 Annual Report posted online.

02-03-2026

Eventbrite, Inc. held a special stockholder meeting on February 27, 2026, approving the Merger Agreement with Bending Spoons US Inc. and Everest Merger Sub Inc. by an overwhelming vote of 212,405,179 for, 1,169,058 against, and 368,438 abstentions out of shares representing 88.7% quorum. The advisory Merger-Related Compensation Proposal (208,701,175 for) and Adjournment Proposal also passed strongly, primarily driven by Class B common stock votes. Prior litigation challenging the merger vote was dismissed as moot following approval under both parties' interpretations of the charter.

• ·Record date for Special Meeting: January 16, 2026
• ·Proxy statement filed: January 28, 2026
• ·Merger closing subject to HSR waiting period, no MAE, and customary conditions
• ·Class B shares carry 10 votes per share vs. 1 for Class A

02-03-2026

On February 27, 2026, CMS notified Elevance Health, Inc. of its intent to impose intermediate sanctions suspending new Medicare Advantage-Prescription Drug (MA-PD) plan enrollments and certain beneficiary communications, effective March 31, 2026, unless resolved, due to alleged noncompliance with risk adjustment data submission requirements for dates of service prior to April 3, 2023. The sanctions do not impact benefits for current MA-PD members. Elevance Health, which revised its practices in April 2023 following regulatory guidance, is engaging cooperatively with CMS to address the concerns.

• ·Sanctions relate specifically to Medicare Advantage risk adjustment data submission requirements for dates of service prior to April 3, 2023.

02-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX), through its subsidiary Robotic Assistance Devices, Inc. (RAD), announced a new channel partner placed an immediate first-day order for two RIO™ 360 units, one ROSA™ system, and three SARA™ software licenses, signaling strong confidence in RAD's expanding channel ecosystem and integrated autonomous security solutions. This aligns with RAD's strategy of scaling via committed multi-system deployments in the nearly $50B USD security industry, where RAD offers 35%-80% cost savings over manned guarding. RAD maintains a prospective sales pipeline with over 35 Fortune 500 companies, though no specific order value or revenue impact was disclosed.

• ·RAD has successfully completed SOC 2 Type 2 audit, validating internal controls for customer data protection.
• ·RAD invites security professionals to ISC West 2026 for live demonstrations and meetings.
• ·All RAD technologies, AI-based analytics, and software platforms are developed in-house.

02-03-2026

EQV Ventures Acquisition Corp. (NYSE: FTW) shareholders approved the business combination with Presidio Investment Holdings LLC, a mature oil and gas operator, at an extraordinary general meeting on February 27, 2026. The transaction is expected to close on or about March 4, 2026, subject to closing conditions, with shares of the combined entity to trade on NYSE under 'FTW' starting March 5, 2026. Presidio anticipates providing dividend details post-closing, highlighting its capital-light platform for shareholder returns, though dividends are not guaranteed and subject to various risks.

• ·EQV sponsored by affiliate of EQV Group, formed in 2022.
• ·Presidio headquartered in Fort Worth, TX, focused on Mid-Continent operations.
• ·A Form 8-K with full voting results to be filed with SEC.
• ·Contacts: Presidio@icrinc.com; IR@eqvventures.com

02-03-2026

Miami International Holdings, Inc. issued 1,033,166 shares of its common stock on February 25, 2026, through cashless exercises of pre-funded warrants and warrants by two warrant holders, in exchange for the surrender of 29,404 shares. This issuance occurred between February 18, 2026, and February 25, 2026, and was made in reliance on the Section 4(a)(2) exemption from Securities Act registration. No cash consideration was received.

• ·Issuance dates: both tranches on February 25, 2026
• ·Warrant exercise price for second tranche: $5.50 per share
• ·Exemption relied upon: Section 4(a)(2) of the Securities Act

02-03-2026

PROG Holdings, Inc. (NYSE:PRG) announced a 7.7% increase in its quarterly cash dividend to $0.14 per share from the prior $0.13 per share, payable on March 24, 2026, to shareholders of record as of March 12, 2026. The Board of Directors declared the dividend on February 25, 2026. No declines or flat metrics were reported in this announcement.

• ·Filing Date: March 02, 2026
• ·Announcement Date: February 25, 2026
• ·Record Date: March 12, 2026
• ·Payment Date: March 24, 2026
• ·Headquartered in Salt Lake City, UT

02-03-2026

TPG RE Finance Trust (TRTX) reported a $4.3B loan portfolio at 100% performing status with a 7.15% weighted average all-in yield as of December 31, 2025, alongside $143M in liquidity and full dividend coverage via $0.24 distributable earnings per share for 4Q25 matching the declared dividend. The company originated $843M in new loans in 4Q25 and repurchased 3.2M shares for $25.3M during FY25, with strong repayments of $987.9M for the year; however, GAAP net income per share was flat at $0.00 for 4Q25, loan risk rating remained unchanged YoY at 3.0, and debt-to-equity rose from 2.14x at year-end 2024 to 3.0x amid increased leverage.

• ·One loan on non-accrual status (<1% of UPB), accounted for on cash basis as of Dec 31, 2025
• ·Redeemed $114.6M of TRTX 2019-FL3 and $411.5M of TRTX 2021-FL4 investment grade securities in FY25
• ·Book value per share $11.07 at Dec 31, 2025; closing share price $8.46 on Feb 25, 2026

02-03-2026

Chaince Digital Holdings Inc. (CD) entered into a Securities Purchase Agreement on February 25, 2026, to sell 6,500,000 ordinary shares at $0.774 per share to non-U.S. investors for a total of $5.03M, under Regulation S exemption. The offering is expected to close on or before March 12, 2026. No financial performance metrics or period comparisons were reported.

• ·Securities registered: Common Shares, par value US$0.004 per share, trading symbol CD
• ·Exemption relied upon: Rule 903 of Regulation S under the Securities Act of 1933
• ·Principal executive offices: 1251 Avenue of the Americas, Fl 41, New York, NY 10019

02-03-2026

NewAmsterdam Pharma released an investor presentation highlighting obicetrapib's clinical progress, including topline results from BROOKLYN, BROADWAY, and TANDEM Phase 3 trials showing 35-40% LDL-C lowering as monotherapy and 45% Lp(a) lowering, with an observed MACE reduction at 1-year and cash position of ~$729M at YE2025 supporting potential US launch if approved. The presentation emphasizes a $8B+ global peak sales opportunity targeting ~30M US patients not at LDL-C goals, beneficial effects beyond LDL-C on ApoB, HDL-C, Lp(a), and other markers, alongside comprehensive IP until mid-2043. Company doubled workforce to ~100 employees while building commercial functions, though forward-looking statements note risks like trial uncertainties and market access hurdles.

• ·~75M US patients with elevated Lp(a) >100-125 nmol/L, ~18M US patients far from LDL-C goal (>20% above), ~5M ASCVD patients not at LDL-C <70 mg/dL, ~8M high-risk ASCVD not at <55 mg/dL
• ·Non-statin LLT growth in high double digits, Repatha +45% Rx growth in 2024
• ·IP protection until mid-2043, blinded data in >9,500 patients

02-03-2026

Klaviyo, Inc. announced on March 2, 2026, that its board of directors authorized a $500M share repurchase program for its Series A Common Stock, with no expiration date and flexibility to modify, suspend, or discontinue. As part of the program, the company plans to imminently enter into a $100M accelerated share repurchase transaction. Repurchases may occur via open market, private negotiations, 10b5-1 plans, or other compliant means.

• ·Filing includes Exhibit 104: Cover Page Interactive Data File (Inline XBRL).

02-03-2026

Xeris Biopharma reported record Q4 2025 total revenue of $86M, up 42.8% YoY, driven by Recorlev net revenue doubling to $45.3M (+100.5%), Gvoke up 5.9% to $24.6M, and Keveyis up 15.1% to $12.8M; however, royalty revenue declined 23.3% to $2.4M. Full-year 2025 total revenue hit a record $292M, up 43.7% YoY, with Recorlev surging 116.7% to $139.3M and Gvoke up 13.6% to $94.1M, but Keveyis fell 3.8% to $47.6M; the company turned profitable with net income of $0.6M vs. prior $54.8M loss and Adjusted EBITDA of $59.4M. FY2026 revenue guidance is $375M-$390M, implying >30% growth at midpoint, with higher R&D (+$25M) and SG&A (+$45M) expenses planned.

• ·COGS increased 16% YoY in both Q4 and FY 2025 due to higher product revenue.
• ·R&D expenses up 29% Q4 and 22% FY 2025, primarily for XP-8121.
• ·SG&A expenses up 18% Q4 ($7.4M) and 12% FY ($18.9M), driven by personnel costs.
• ·FY2026 outlook: R&D +$25M, SG&A +$45M vs. 2025, gross margin modest improvement, Adjusted EBITDA dollar increase.

02-03-2026

uniQure reported 2025 full-year financial results showing cash and equivalents rising 69% to $622.5M from $367.5M in 2024, sufficient to fund operations into H2 2029, bolstered by $404.2M in net proceeds from offerings; however, revenues fell 40% YoY to $16.1M due to lower collaboration and contract manufacturing income, while SG&A expenses increased 24% to $65.5M. Clinical highlights included 36-month AMT-130 data demonstrating 75% slowing in Huntington’s disease progression (cUHDRS) and 60% in TFC versus external controls, but FDA declined to accept Phase I/II data for approval, recommending a Phase III trial; AMT-260 and AMT-191 showed promising efficacy, though dosing pauses occurred in AMT-191 and enrollment in AMT-162. Net loss narrowed 17% to $199.0M from $239.6M YoY.

• ·Refinanced $50M debt to October 2030 with optional $100M tranche tied to AMT-130 milestone and $25M subject to lender approval.
• ·Type A FDA meeting in January 2026; plans for Type B meeting in Q2 2026 to discuss Phase III for AMT-130.
• ·AMT-191 dosing paused in mid- and high-dose cohorts due to asymptomatic Grade 3 liver enzyme elevations (dose-limiting toxicities).
• ·AMT-162 enrollment on voluntary pause after one related serious adverse event.
• ·Upcoming conferences: TD Cowen (March 2, 2026), Leerink (March 11), Barclays (March 12), Kempen (April 15).

02-03-2026

GeneDx Holdings Corp. entered into a $100M term loan agreement with Blackstone on February 27, 2026, to fully repay its existing credit agreement dated October 27, 2023, with Perceptive Credit Holdings IV, LP, and support balance sheet optimization and general corporate purposes. The new five-year loan bears interest at Term SOFR plus 4.50% (with a 1.50% floor), is secured by substantially all assets, and includes a $50M minimum liquidity covenant. No performance metrics or declines were reported in the filing.

• ·Term Loan prepayable at option but subject to yield protection premiums and mandatory prepayments on change of control, asset sales, or certain indebtedness.
• ·Obligations guaranteed by certain subsidiaries.
• ·Loan Agreement to be filed as exhibit to Q1 2026 10-Q.

02-03-2026

Shoulder Innovations, Inc. (NYSE: SI) appointed MedTech veteran Drew Hykes to its Board of Directors and Compensation Committee effective February 26, 2026, bringing over 25 years of experience from Inari Medical, Medtronic, and others to support scaling its shoulder arthroplasty portfolio. Concurrently, Independent Director Geoff Pardo resigned after three years of service, with the company expressing gratitude for his contributions. No financial impacts or performance metrics were disclosed.

• ·Drew Hykes served as CEO of Inari Medical from 2023 until its acquisition by Stryker in 2025, and previously as COO and Chief Commercial Officer there.
• ·Hykes led commercialization of WEB Aneurysm Embolization system at Sequent Medical before its acquisition by Terumo.
• ·Contact: Brian Johnston or Sam Bentzinger, Gilmartin Group LLC, ir@shoulderinnovations.com

02-03-2026

Jeffrey D. Bitzer will resign as Chief Development Officer of Coronado Global Resources Inc. effective February 28, 2026, following prior disclosure. On February 26, 2026, he entered a part-time Employment Agreement effective March 1, 2026, for a six-month transition period assisting the Board and management, with monthly compensation of $27,000 and eligibility for employee benefits, retained incentives, and a 2025 short-term incentive payment.

• ·Agreement includes eligibility to retain incentive units in Coronado Group LLC and outstanding Performance Share Units, subject to performance metrics
• ·Mr. Bitzer agreed to execute a general release and remains bound by non-disclosure and confidentiality provisions
• ·Short-term incentive payment under 2025 program to be paid in March 2026

02-03-2026

Glaukos Corporation released its March 2026 investor presentation, reporting 30% topline growth in 2025 and a 20% 10-year revenue CAGR, driven by leadership in interventional glaucoma and keratoconus markets with products like iDose TR and upcoming Epioxa. The company highlighted a 13-program pipeline, $800M invested in R&D since 2018, and strong clinical data such as 81% of iDose TR subjects free of IOP-lowering meds at 12 months. While forward-looking, the presentation notes risks including commercialization challenges and regulatory hurdles, with no current declines but emphasis on patient non-compliance issues (90%) as market opportunities.

• ·iDose TR FDA-approved for re-administration in Jan 2026; Epioxa commercially available in 1Q 2026
• ·IND amendment for iDose TRIO filed Dec 2025; Phase 3b study commenced recently
• ·Phase 2a initial results for iDose TREX: mean IOP reductions of 8.6-10.8mmHg through Month 3
• ·90% user favorability in initial human factors study for iDose TRIO

02-03-2026

Civista Bancshares, Inc. announced that President and CEO Dennis Shaffer will retire effective August 28, 2026, and will be succeeded by Charles 'Chuck' Parcher, current President of Civista Bank, who will assume the roles of President and CEO for both the holding company and bank. Shaffer will remain as Chairman of the Board to ensure a seamless transition after more than 40 years of service. The $4.3B financial holding company operates 44 locations across Ohio, Southeastern Indiana, and Northern Kentucky.

• ·Civista Bank founded in 1884.
• ·Dennis Shaffer has more than 40 years of service in the banking industry.
• ·Common shares traded on NASDAQ Capital Market under symbol 'CIVB'.
• ·Filing date: March 02, 2026.

02-03-2026

Farmers National Banc Corp. (FMNB) completed its merger with Middlefield Banc Corp. (MBCN) on March 2, 2026, boosting banking assets to over $7.4B from $5.2B as of December 31, 2025 (42% increase) and expanding branches to 83 from 62. The company added two new board members, Kevin A. DiGeronimo and Michael C. Voinovich, while wealth management assets under care remained at over $4.7B. This marks FMNB's seventh bank acquisition in the last decade, enhancing its footprint in Ohio and Pennsylvania.

• ·Operates 83 branches throughout Ohio and Pennsylvania
• ·Forward-looking statements highlight integration risks and economic uncertainties

02-03-2026

Intellia Therapeutics, Inc. amended its Open Market Sale Agreement with Jefferies LLC, increasing the total value of Common Shares issuable from $750M to $1,035,316,650, representing a 38% expansion of the ATM offering capacity. The amendment updates the issuance notice reference and changes the company contact from Glen Goddard to Edward Dulac. The company must file a Prospectus Supplement within two business days of March 2, 2026.

• ·Original Sales Agreement dated March 4, 2022, previously amended February 23, 2024
• ·Prospectus Supplement to be filed pursuant to Rule 424(b) within two Business Days
• ·Governed by New York law

02-03-2026

Xtant Medical Holdings, Inc. received a $10.7M payment from Companion Spine on February 27, 2026, representing full repayment of an $8.2M promissory note plus interest and purchase price adjustments for the December 1, 2025 divestiture of Coflex and CoFix product assets and subsidiary Paradigm Spine GmbH, increasing total consideration from $19.2M to $21.4M. The company applied $2.8M of the proceeds to prepay a portion of its term loan with MidCap Financial Trust, leaving $11.1M in principal outstanding. This transaction provides liquidity and reduces debt without any reported declines or issues.

• ·Promissory note was scheduled to mature on January 31, 2026
• ·Divestiture announced previously on December 1, 2025

02-03-2026

CCC Intelligent Solutions Holdings Inc. appointed John A. Schweitzer as a Class II Director effective March 2, 2026, leveraging his extensive experience as former EVP, Sales at Salesforce (Informatica division), EVP and Chief Revenue Officer at Informatica, and senior roles at Software AG, Workday, SAP, and Oracle. The Board determined Mr. Schweitzer to be independent under applicable rules and reconstituted the Nominating and Corporate Governance Committee by appointing Teri Williams as chairperson and adding Mr. Eilam and Mr. Schweitzer, resulting in Mr. Wei no longer serving on the committee. Mr. Schweitzer will receive standard non-employee director compensation as detailed in the company's April 8, 2025 proxy statement.

• ·Mr. Schweitzer joined Salesforce in November 2025 via its acquisition of Informatica and served as EVP, Chief Revenue Officer at Informatica from March 2021, including through its IPO in November 2021.
• ·No family relationships, arrangements, or reportable transactions under Item 404(a) of Regulation S-K involving Mr. Schweitzer.

02-03-2026

Classover Holdings Inc. (NASDAQ:KIDZ, KIDZW) terminated its $400M Equity Purchase Facility Agreement with Solana Strategic Holdings LLC, formally ending its Solana-focused digital asset treasury strategy, which the Board deemed no longer accretive under current market conditions. This move eliminates potential share dilution and redirects capital toward AI, AI agents, and robotics initiatives aligned with its educational technology mission. The company maintains a healthy balance sheet with no imminent liquidity needs and has not sold its existing Solana holdings, which will be evaluated for future divestment.

• ·Announcement date: March 2, 2026
• ·SEC filing date: March 02, 2026
• ·Items reported: 1.02, 9.01

02-03-2026

Ondas Holdings Inc. (ONDS) announced a $10 million strategic investment in World View Enterprises, Inc. and entered a partnership agreement to collaborate on multi-domain ISR solutions integrating World View's stratospheric balloon systems with Ondas' autonomous aerial and ground systems. The partnership targets defense (U.S. Department of War), homeland security (DHS), allied organizations, and critical infrastructure customers, with focus on layered ISR, mission applications, and joint go-to-market strategies. No prior period financial comparisons or declines are reported in the filing.

• ·Filing date: March 02, 2026
• ·Press release date: March 2, 2026
• ·Target customers include U.S. Department of War (DoW), Department of Homeland Security (DHS), allied defense organizations, and critical infrastructure operators

02-03-2026

Avalon GloboCare Corp. (NASDAQ: ALBT) announced a private placement priced at-the-market under Nasdaq rules, issuing 6,372,550 shares (or pre-funded warrants) and two series of warrants to purchase up to 6,372,550 shares each at $0.51 per share, expecting $3.25M upfront gross proceeds and up to $6.5M additional if warrants are fully exercised. H.C. Wainwright & Co. acts as exclusive placement agent, with closing expected on or about February 27, 2026, subject to customary conditions; proceeds for debt repayment and working capital. No assurance is given that warrants will be exercised.

• ·Purchase price and warrant exercise price: $0.51 per share
• ·Series A-1 warrants expire five years from stockholder approval; Series A-2 expire eighteen months from approval
• ·Warrants exercisable beginning on effective date of stockholder approval
• ·Securities offered under Section 4(a)(2) and Regulation D to accredited investors; registration rights for resale
• ·Press release dated February 26, 2026; 8-K filing March 02, 2026

02-03-2026

Forge Global Holdings, Inc. filed an 8-K on March 02, 2026, disclosing completion of an acquisition/disposition (Item 2.01), notice of delisting (Item 3.01), material modification to security holder rights (Item 3.03), changes in control (Item 5.01), director/officer changes (Items 5.02/5.03), and an Amended & Restated Certificate of Incorporation as Exhibit 3.1. The amended certificate drastically simplifies the capital structure to a single class of Common Stock authorized at 100 shares with $0.01 par value, indicating a likely privatization or merger restructuring with no prior period financial comparisons provided.

• ·Registered office: 1209 Orange Street, Wilmington, County of New Castle, Delaware 19808
• ·8-K Items disclosed: 2.01 (Acquisition/Disposition Completion), 3.01 (Delisting Notice), 3.03 (Material Modification to Rights of Security Holders), 5.01 (Changes in Control), 5.02 (Departure/Election of Directors/Officers), 5.03 (Amendments to Articles), 9.01 (Exhibits)

02-03-2026

Kennedy-Wilson Holdings, Inc. announced the launch of exchange offers for any and all of its $1.8B outstanding senior notes ($600M each of 4.750% due 2029, 4.750% due 2030, and 5.000% due 2031) for new higher-coupon notes (6.125% due 2032 or 6.375% due 2034, capped at $906M each), alongside consent solicitations, conditioned on the closing of its pending merger with a consortium led by CEO William McMorrow and Fairfax Financial Holdings Limited. Supporting holders represent 19% of 2029 notes, 35% of 2030 notes, 27% of 2031 notes (27% aggregate), with early participation premium for tenders by March 13, 2026 (Expiration March 30, 2026). While facilitating the merger, the exchange increases interest costs on refinanced debt.

• ·Merger Agreement dated February 16, 2026; Early Participation Date and Withdrawal Deadline: March 13, 2026 (5:00 p.m. NYC time); Expiration Date: March 30, 2026; Expected Settlement: second business day after Expiration.
• ·Total Consideration (early tenders): $1,000/$1,010 principal of New Notes; Exchange Consideration (late): $950 principal.
• ·New Notes guaranteed by Company and subsidiaries; interest payable semi-annually April 15/October 15 starting October 15, 2026.
• ·Conditions include Merger closing and majority consents per series; only for Eligible Holders (QIBs or non-U.S. persons).

02-03-2026

Vir Biotechnology, Inc. closed a public offering on February 27, 2026, selling 20,294,117 shares of common stock at $8.50 per share, which included the full exercise of the underwriters' option for an additional 2,647,058 shares. The company received aggregate gross proceeds of approximately $172.5 million before deducting underwriting discounts, commissions, and estimated offering expenses. This follows an underwriting agreement dated February 25, 2026, with Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C., and Barclays Capital Inc. as representatives.

• ·Underwriting agreement dated February 25, 2026
• ·Underwriters' option exercisable for 30 days, exercised in full on February 26, 2026
• ·Common stock par value $0.0001 per share
• ·Public offering price $8.50 per share

02-03-2026

Virtus Investment Partners, Inc. (NYSE: VRTS) completed its previously announced majority investment in Keystone National Group effective March 1, 2026, expanding its capabilities into private markets with Keystone's asset-backed lending strategies including equipment finance, real estate finance, financial assets, and asset-backed corporate loans. As of December 31, 2025, Keystone managed $2.5B in assets and has invested over $6.0B across more than 750 transactions. CEO George R. Aylward noted the strategic fit with Virtus' multi-boutique model, while Keystone's team retains autonomy and a significant equity stake.

• ·Keystone founded in 2006 and headquartered in Salt Lake City, Utah
• ·Transaction completed effective March 1, 2026

02-03-2026

UnitedHealth Group Incorporated appointed Dennis Stankiewicz, age 48, as Chief Accounting Officer effective March 2, 2026, while he continues serving as Corporate Controller since April 17, 2023. Tom Roos, who has been Chief Accounting Officer since August 2015, will transition to Chief Financial Officer of Optum Insight effective the same date. Stankiewicz's compensation includes an annual base salary of $550,000, an initial cash bonus target of 85% of base salary, and severance of one times base salary upon termination without cause.

• ·Dennis Stankiewicz joined UnitedHealth Group in August 2016 as General Auditor and has more than 24 years of professional experience.
• ·Mr. Stankiewicz has not been involved in any transactions requiring disclosure under Item 404(a) of Regulation S-K.
• ·Severance benefits for Stankiewicz conditioned on non-compete during severance period.

02-03-2026

First Mid Bancshares, Inc. (NASDAQ: FMBH) completed its acquisition of Two Rivers Financial Group, Inc. on March 2, 2026, adding approximately $1.2B in assets, $883M in loans, $1.0B in deposits, and over $1.2B in trust and wealth assets under management across 14 Iowa locations as of December 31, 2025. Post-acquisition, First Mid's total assets stand at $9.1B and total trust and wealth AUM at $7.9B, with no immediate changes for Two Rivers customers and account conversion expected in June 2026. The transaction positions First Mid to expand services in new markets without reported disruptions.

• ·Two Rivers financials reported as of December 31, 2025
• ·Account conversion from Two Rivers expected in June 2026
• ·First Mid operates in Illinois, Missouri, Texas, Wisconsin, and greater Indianapolis area

02-03-2026

Home BancShares, Inc. (HOMB) filed an 8-K with supplemental disclosures to the proxy statement/prospectus for its pending merger with Mountain Commerce Bancorp, Inc. (MCBI), announced December 7, 2025, to address shareholder requests without admitting any legal requirement. The supplements detail standstill provisions in prior NDAs (most expired, one remains until March 6, 2026, with no post-announcement contacts), update Piper Sandler & Co.'s comparable company analyses showing MCBI's total assets at $1.8B and ROAA of 0.64% versus Home's $22.7B assets and 2.01% ROAA, and add discount rate details (10.86%) for net present value analyses. No period-over-period financial performance data or merger timeline updates provided.

• ·Registration Statement on Form S-4 (File No. 333-292708) filed January 13, 2026, amended January 29, 2026, effective January 30, 2026.
• ·Proxy statement/prospectus mailed to MCBI shareholders on or about January 30, 2026.
• ·Standstill provisions in NDAs: expired for all but one as of March 1, 2026; remaining expires March 6, 2026.
• ·No contacts from prior NDA parties regarding acquisition since Merger announcement.
• ·Piper Sandler discount rate components: Risk Free Rate 4.75%, Equity Risk Premium 5.00%, Size Premium 2.66%, Industry Premium -1.55%.

02-03-2026

On February 27, 2026, The Cannabist Company Holdings Inc. entered into a further extension of a forbearance agreement with an ad hoc group of noteholders holding the Company's 9.25% Senior Secured Notes due December 31, 2028, and 9.00% Senior Secured Convertible Notes due December 31, 2028, extending the forbearance period until March 6, 2026. This prevents noteholders from exercising rights and remedies under the indenture amid presumed covenant or payment issues. The agreement signals ongoing financial pressures with no disclosed resolution or positive developments.

• ·Registrant is an emerging growth company.
• ·Principal executive offices: 321 Billerica Road, Chelmsford, Massachusetts 01824.

02-03-2026

On March 1, 2026, the Board of Directors of Plumas Bancorp adopted a new form of restricted stock unit award agreement under the Plumas Bancorp 2022 Equity Incentive Plan for grants to directors, executives, and employees. The new agreement features time-based vesting tied to continued service, with no cash dividends or dividend equivalents on unvested units—unlike the prior form—entitling participants only to dividends on vested shares. This update is filed as Exhibit 10.1.

02-03-2026

LSEB Creative Corp. filed a Certificate of Amendment to its Articles of Incorporation, restating Article V to authorize a total of 505,000,000 shares of capital stock, comprising 500,000,000 shares of Common Stock (par value $0.0001 per share) and 5,000,000 shares of Preferred Stock (par value $0.0001 per share). The amendment empowers the Board of Directors to designate series of Preferred Stock with customizable terms such as dividend rates, voting rights, and conversion rights. It was approved by the Board and a majority of shareholders, effective upon filing with the Wyoming Secretary of State on March 02, 2026.

• ·Holders of Common Stock have one vote per share and are entitled to dividends and remaining assets after Preferred Stock rights in liquidation.
• ·Preferred Stock holders have no preemptive rights except as required by law.
• ·Amendment adopted in accordance with the Wyoming Business Corporation Act.

02-03-2026

Dakota Gold Corp.'s Board of Directors appointed Brian G. Iverson as a director on February 26, 2026, effective March 1, 2026; he will stand for election by stockholders at the 2026 Annual Meeting of Stockholders. Mr. Iverson will participate in the non-employee director compensation program outlined in the 2025 proxy statement, with no committee assignments determined yet. There are no arrangements, family relationships with directors/officers, or material interests under Item 404(a) of Regulation S-K.

• ·Company address: 106 Glendale Drive, Suite A, Lead, South Dakota 57754
• ·Registrant is an emerging growth company

02-03-2026

Calavo Growers, Inc. filed an 8-K/A on March 2, 2026, amending its January 14, 2026 8-K to correct a clerical error in Exhibit 10.1 and clarify severance provisions in Executive Retention Agreements entered with CFO James Snyder and Executive VP Ronald Araiza of the Calavo Foods Division. The agreements amend prior offer letters and provide for severance equal to one year of base salary if the executive resigns for Good Reason or is terminated without Good Cause, subject to execution of a release. No other changes or financial impacts were reported.

• ·Agreements amend compensatory provisions of existing offer letters.
• ·Full text of Retention Agreement form filed as Exhibit 10.1.

02-03-2026

Vitesse Energy announced an accretive $35M all-stock acquisition of non-operated Powder River Basin assets expected to add 1,400 Boe/d production in 2026, alongside FY2025 results showing production up 34% YoY to 17,444 Boe/d (65% oil), Adjusted EBITDA of $179.3M, and Free Cash Flow of $48.9M; however, realized oil prices declined 12% YoY to $62.95/Bbl with hedging, Q4 production fell 3% sequentially to 17,653 Boe/d, and Q4 reported a net loss of $0.7M. Total proved reserves grew 19% YoY to 47.8M Boe but PV-10 value dropped 19% to $472.7M due to lower SEC oil prices. 2026 guidance projects 16,000-17,500 Boe/d production and $50-80M capex, reflecting a decline from 2025 levels.

• ·Q1 2026 dividend of $0.4375 per share payable March 31, 2026; Q4 2025 dividend was $0.5625 per share.
• ·Net Debt to Adjusted EBITDA ratio of 0.69x at year-end.
• ·2026 guidance: oil 60-64% of production; capex $50-80M.

02-03-2026

American Express Company announced an increase in its quarterly dividend on common shares to $0.95 per share from the previous $0.82 per share, effective with the announcement on March 2, 2026. This represents an approximately 15.9% increase, signaling confidence in financial stability and shareholder returns.

• ·Filing submitted under Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits).
• ·Press release attached as Exhibit 99.1.

02-03-2026

On February 24, 2026, Christopher J. Klein notified Vontier Corporation's Board of his decision to retire as a director effective at the 2026 Annual Meeting of Shareholders, where he will not stand for re-election. This follows his support during the Company's spin-off and is not due to any disagreement with the Company's operations. The 8-K was filed on March 2, 2026.

• ·Company's principal executive offices: 5438 Wade Park Boulevard, Suite 600, Raleigh, NC 27607
• ·I.R.S. Employer Identification No.: 84-2783455

02-03-2026

Sunbelt Rentals Holdings, Inc. (NYSE: SUNB) announced the commencement of trading its common stock on the NYSE under ticker SUNB, completing the transition to a U.S. primary listing with a secondary listing retained on the London Stock Exchange; former Ashtead Group plc shareholders received one Sunbelt share per Ashtead share held. The company, with 24,000 employees across more than 1,600 locations and a fleet exceeding $19B, highlighted its leadership in North American equipment rentals amid growing industry demand. No financial declines or flat metrics were reported, positioning Sunbelt for enhanced U.S. capital market access and growth.

• ·Earnings call scheduled for March 12, 2026 at 8:30 a.m. Eastern Time
• ·Investor Day on March 26, 2026 to cover strategic roadmap, performance, and capital allocation
• ·Registration Statement on Form 10 filed February 13, 2026

02-03-2026

Metropolitan Bank Holding Corp. announced its Investor Day on March 3, 2026, from 9:30 a.m. to 1:30 p.m. ET, featuring presentations and Q&A with executives including Founder, President & CEO Mark DeFazio and EVP & CFO Dan Dougherty on topics such as commercial lending (including skilled nursing and residential healthcare), diverse deposit verticals (including EB-5 solutions), and technology/AI initiatives. The Investor Day presentation is attached as Exhibit 99.1, with a live webcast available via registration.

• ·Investor Day webcast registration: https://app.webinar.net/kW1BqVW4jlr.
• ·Information in Item 7.01 and Exhibit 99.1 not deemed 'filed' or incorporated by reference

02-03-2026

James River Group Holdings reported Q4 2025 net income available to common shareholders of $30.1M ($0.53/share) versus a $94.0M loss in Q4 2024, with combined ratio improving to 94.1% from 155.1% and underwriting profit of $8.6M versus a $58.1M loss, driven by E&S segment net earned premium growth of 61% to $140.9M and combined ratio of 86.0%. However, overall gross written premium declined 27% to $262.7M due to a 70% drop in Specialty Admitted to $23.2M and strategic reductions in E&S, while net investment income fell 4% to $21.0M. Full year combined ratio was 96.6% with tangible common equity up 35% to $411M, but E&S gross written premium declined 5%.

• ·Dividend of $0.01 per share declared, payable March 31, 2026 to shareholders of record March 13, 2026.
• ·Conference call scheduled for March 3, 2026 at 8:30 a.m. ET.
• ·Sale of JRG Reinsurance Company Ltd. closed April 16, 2024, classified as discontinued operations.
• ·Net favorable reserve development of $1.8M in Q4 2025 ($5.0M E&S favorable, $3.1M Specialty unfavorable).

02-03-2026

On February 24, 2026, Southern California Edison Company (SCE) agreed to sell $600M principal amount of its 5.15% First and Refunding Mortgage Bonds, Series 2024D, due 2029, and $600M principal amount of its 4.80% First and Refunding Mortgage Bonds, Series 2026A, due 2033. The Form 8-K filing, dated March 2, 2026, includes exhibits such as the Underwriting Agreement dated February 24, 2026, and Supplemental Indentures.

• ·Filing submitted on March 2, 2026, reporting event of February 24, 2026.
• ·Exhibits include One Hundred Fifty-Seventh Supplemental Indenture dated February 28, 2024 (incorporated by reference) and One Hundred Sixty-Second Supplemental Indenture dated February 25, 2026.

02-03-2026

On March 2, 2026, the Compensation Committee of the Board of Directors of Reliance Global Group, Inc. (NASDAQ: EZRA) approved and ratified a one-time cash bonus of $50,000 for Joel Markovits, the Company's Chief Financial Officer, subject to tax withholding and deductions. The filing pertains to Item 5.02 under compensatory arrangements for certain officers, with no departures, elections, or appointments reported.

• ·Securities registered: Common Stock (EZRA, par value $0.086 per share) and Series A Warrants (EZRAW) on The NASDAQ Capital Market.
• ·Company address: 300 Blvd. of the Americas, Suite 105, Lakewood, New Jersey 08701.
• ·IRS Employer Identification No.: 46-3390293.

02-03-2026

Finward Bancorp's Board of Directors declared a quarterly dividend of $0.12 per share on its common stock, payable on March 31, 2026, to shareholders of record on March 16, 2026. This announcement comes amid ongoing regulatory oversight, as Peoples Bank operates under a previously disclosed memorandum of understanding with the FDIC and Indiana DFI that generally requires prior approval for cash dividends. No other financial metrics or period-over-period comparisons were provided.

• ·Filing signed by Benjamin L. Schmitt, EVP, CFO, and Treasurer.
• ·Registrant details: Indiana incorporation, Commission File Number 001-40999, IRS EIN 35-1927981, principal offices at 9204 Columbia Avenue, Munster, Indiana 46321.

02-03-2026

Fidus Investment Corporation entered into Amendment No. 3 to its Equity Distribution Agreement, increasing the maximum aggregate offering amount under its at-the-market (ATM) program from $300.0M to $400.0M. As of March 2, 2026, approximately $134.8M remains available for sale through sales agents Fidus Investment Advisors, LLC, Raymond James & Associates, Inc., and B. Riley Securities, Inc. No shares were sold in connection with this amendment.

• ·Original Equity Distribution Agreement dated November 10, 2022
• ·Prospectus supplement filed March 2, 2026 (accompanying prospectus dated February 27, 2026)
• ·Shelf registration on Form N-2 (File No. 333-293856)

02-03-2026

Dave Inc. reported record Q4 2025 revenue of $163.7 million, up 62% YoY from $100.9 million, and FY 2025 revenue of $554.2 million, up 60% YoY from $347.1 million. GAAP net income grew 292% to $66.0 million in Q4 and 238% to $195.9 million for the year, while Adjusted EBITDA increased 118% to $72.9 million in Q4 and 162% to $226.7 million annually, though quarterly GAAP net income showed volatility with a 16% decline in Q1 2025. The company provided FY 2026 guidance for revenue growth of 25%-28% to $690-$710 million and raised its share repurchase authorization from $125 million to $300 million.

• ·Q4 2025 Non-GAAP Gross Profit Margin of 74%, up 300 bps YoY.
• ·Q4 2025 average 28-day past due rate improved 12% QoQ to 1.89%.
• ·Q4 2025 Dave Debit Card spend increased 17% YoY to $534 million.
• ·Q4 2025 ExtraCash Monetization Rate Net of Losses at record 4.8%, up 29 bps YoY.
• ·FY 2026 Adjusted EBITDA guidance $290-$305 million; Adjusted EPS $14.00-$15.00.

02-03-2026

Lumentum Holdings Inc. filed a Certificate of Designation authorizing 2,876,415 shares of Series A Convertible Preferred Stock with a par value of $0.001 per share, featuring a 1:1 conversion ratio into common stock, pro-rata dividend rights, as-converted voting rights, and pro-rata liquidation preferences. The board adopted the resolution on March 1, 2026, in connection with a Stock Purchase Agreement dated March 2, 2026, with NVIDIA Corporation. No financial impacts or performance metrics are disclosed in the filing.

• ·Conversion Ratio initially 1 share of Series A Preferred to 1 share of Common Stock, subject to adjustments.
• ·Holders have conversion rights subject to Hart-Scott-Rodino waiting period if applicable.
• ·Automatic conversion upon Qualified Sale.
• ·Corporation must reserve sufficient Common Stock for conversions.

02-03-2026

Gloo announced preliminary Q4 2025 results expecting revenue of $32M, exceeding guidance of $28-30M and consensus of $29M, with Adjusted EBITDA at the better end of negative $19.5-18.5M guidance versus consensus negative $19.1M. The company raised FY2026 revenue guidance to $185M from $180M and provided Q1 2026 guidance of $36M revenue (above $33.2M consensus) and negative $12M Adjusted EBITDA (above negative $14.4M consensus), expecting over 30% sequential Adjusted EBITDA improvement from Q4 2025. While progress toward Adjusted EBITDA profitability is accelerating (breakeven approach in Q3 2026, profitability in Q4 2026), results remain preliminary and unaudited with ongoing losses.

• ·Q4 2025 results subject to completion of financial closing and potential adjustments; not audited.
• ·Fireside chat at The Citizens Technology Conference on March 3, 2026, at 12:30 p.m. PT.
• ·Serves over 140,000 faith, ministry, and nonprofit leaders.

02-03-2026

SEI Investments Company (SEIC) filed an 8-K on March 2, 2026, under Items 7.01 and 9.01, furnishing its Raymond James Institutional Investor Conference presentation (Exhibit 99.1) as Regulation FD Disclosure. The filing includes standard forward-looking statements regarding sales momentum, operating model reshaping, earnings growth, strategic priorities, and market opportunities, with disclaimers referencing risks in the 2025 10-K. No specific financial metrics or period comparisons are disclosed in the filing.

• ·References Annual Report on Form 10-K for year ended Dec. 31, 2025
• ·Securities: Common Stock, par value $0.01 per share (SEIC on NASDAQ)

02-03-2026

BigBear.ai reported Q4 2025 revenue of $27.3M, down 38% YoY from $43.8M primarily due to lower Army program volume, with gross margin declining to 20.3% from 37.4% and Adjusted EBITDA swinging to a loss of $10.3M from a $2.0M profit; full-year 2025 revenue fell 19% to $127.7M from $158.2M. However, the company strengthened its balance sheet significantly, ending 2025 with $462M in total cash and investments—the strongest in its history—after raising $693M via ATM facilities and warrants, settling the remaining $125M of 2029 Convertible Notes, and completing acquisitions of Ask Sage and CargoSeer. BigBear.ai guides for 2026 full-year revenue of $135M-$165M, implying 17% growth at the midpoint.

• ·Q4 2025 impairment of long-lived assets $53.4M and full-year goodwill impairment $70.6M.
• ·Settled remaining $125M of 2029 Convertible Notes (originally $182M at start of 2025) primarily via debt-to-equity conversion in Jan 2026.
• ·Debt reduced by more than 90%.
• ·Ask Sage acquisition in Dec 2025 was the largest in company history, net cash outflow $229M; CargoSeer closed Jan 2026.
• ·Q4 2025 net loss $5.8M vs $138.2M in Q4 2024, aided by $50.2M non-cash gain on derivatives and $21.7M tax benefit.

02-03-2026

Bakkt Holdings, Inc. announced the pricing of a $48.125M registered direct offering of 3,024,799 shares of Class A common stock and pre-funded warrants to purchase 2,475,201 shares at approximately $8.75 per share/warrant to a single institutional investor, expected to close on or around March 2, 2026. Gross proceeds will fund working capital, general corporate purposes, and strategic initiatives, with Cohen & Company Capital Markets as sole placement agent. No comparative financial metrics were provided, and the announcement includes extensive forward-looking risk disclosures but no quantitative declines.

• ·Offering pursuant to shelf registration statement on Form S-3 (File No. 333-288361) effective July 3, 2025.
• ·Pricing announced February 27, 2026; expected closing on or around March 2, 2026, subject to customary conditions.
• ·Pre-funded warrants have $0.0001 per share exercise price.

02-03-2026

Baker Hughes Company filed an 8-K on March 2, 2026, reporting on February 27, 2026, and attaching the audited consolidated financial statements of Chart Industries, Inc. as of December 31, 2025 and 2024, and for the three years ended December 31, 2025, in connection with the previously announced merger agreement dated July 28, 2025. The filing includes the consent of Deloitte & Touche LLP as Exhibit 23.1. No specific financial metrics, changes, or performance data are disclosed in the narrative.

• ·Securities registered: Class A Common Stock (BKR, Nasdaq), 5.125% Senior Notes due 2040 (BKR40, Nasdaq)
• ·Principal executive offices: 575 N. Dairy Ashford Rd., Suite 100, Houston, Texas 77079-1121

02-03-2026

On February 25, 2026, the Board of Directors of Goldman Sachs BDC, Inc. reduced its size from seven to six members due to a vacancy from a director's retirement effective December 31, 2025. To balance director classes per the company's certificate of incorporation, Timothy J. Leach and Katherine P. Uniacke were reclassified and appointed as Class III directors, with Leach retaining his role as Chairman of the Board and multiple committees.

• ·Class III directors will hold office until the 2026 annual meeting of stockholders or until successors are elected.
• ·Neither Leach nor Uniacke has family relationships with current directors or officers, nor any material transactions under Item 404(a) of Regulation S-K.

02-03-2026

Nuvation Bio reported strong IBTROZI adoption with 216 new patient starts in Q4 2025 (total 432 since June 2025 launch, 6x prior ROS1 TKI launches) and net product revenue of $15.7M for Q4 ($24.7M FY2025), alongside collaboration revenue of $26.2M in Q4 (up from $5.7M YoY due to $25M Nippon Kayaku milestone). Cash position remained robust at $529.2M as of Dec 31, 2025; however, R&D expenses rose 17% YoY to $34.3M in Q4 and SG&A surged 54% to $40.3M, contributing to a Q4 net loss of $36.6M (improved from $49.4M) and FY net loss of $204.6M (vs $567.9M prior year).

• ·Entered exclusive license and collaboration with Eisai on Jan 11, 2026 for taletrectinib in Europe and select countries.
• ·Safusidenib Phase 2 results published Nov 8, 2025 in Neuro-Oncology; first patient enrolled in SIGMA Phase 3 in Oct 2025.
• ·IBTROZI approved by FDA June 11, 2025 for ROS1+ NSCLC.

02-03-2026

Voya Financial, Inc. completed a $400M registered public offering of 5.050% Senior Notes due 2036 on March 2, 2026, fully guaranteed by its wholly-owned subsidiary Voya Holdings Inc., yielding net proceeds of approximately $395.2M after commissions and expenses. Proceeds are intended for general corporate purposes, potentially including repayment of the $447M outstanding 3.65% Senior Notes due June 15, 2026. No declines or flat metrics reported in this debt issuance event.

• ·Notes issued under Base Indenture dated July 13, 2012, supplemented by Tenth Supplemental Indenture dated March 2, 2026.
• ·Interest payable semi-annually on March 2 and September 2, beginning September 2, 2026.
• ·Voya may redeem Notes in whole or in part at any time at prices specified in Supplemental Indenture.
• ·Underwriting Agreement dated February 23, 2026, with Citigroup Global Markets Inc., BofA Securities, Inc., and Wells Fargo Securities, LLC as representatives.

02-03-2026

Stewart Information Services Corporation (STC) announced that its Board of Directors declared a cash dividend of $0.525 per share on its common stock for the first quarter 2026. The dividend is payable on March 31, 2026, to common stockholders of record on March 16, 2026. This declaration was disclosed via press release on March 2, 2026, under Regulation FD.

• ·Common stock trades on NYSE under ticker STC
• ·Registrant incorporated in Delaware, principal office at 1360 Post Oak Blvd, Suite 100, Houston, Texas 77056

02-03-2026

Biohaven reported $322M in cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2025, bolstered by post-period net proceeds of $178.9M from issuing 17.2M common shares, including a $125M gross directed sale to Janus Henderson Investors. The company highlighted strong pipeline progress, including up to 87% IgG reductions with BHV-1300 in Graves' disease (pivotal H2 2026), >60% Gd-IgA1 reductions with BHV-1400 in IgAN (pivotal Q1 2026), ≥50% seizure reductions with opakalim in epilepsy OLE (pivotal H2 2026), and Phase 2 initiation for taldefgrobep in obesity (topline H2 2026). However, Biohaven initiated Q4 2025 restructuring targeting ~60% reduction in annual direct R&D spend to prioritize these three late-stage programs.

• ·Entered MoU with KAUST in Jan 2026 for discovery collaboration leveraging AI and supercomputing.
• ·Nov 2025 restructuring to achieve ~60% cut in annual direct R&D spend (ex-personnel/SBC).
• ·April 2025 Oberland investment: $250M funded, $150M on troriluzole milestones, up to $200M for acquisitions.
• ·Pivotal studies planned: BHV-1400 IgAN Q1 2026; BHV-1300 Graves' H2 2026; opakalim epilepsy H2 2026; taldefgrobep obesity Phase 2 topline H2 2026.

02-03-2026

On February 25, 2026, Live Oak Acquisition Corp. V appointed Somak Chivavibul, age 59, as a Class I independent director, effective immediately, with membership on the audit committee and as chair of the compensation committee. Mr. Chivavibul brings over 25 years of public company financial management experience from roles at Navient Corporation (CFO 2014-2017), Sallie Mae, and Ernst & Young. No family relationships or disclosable transactions under Item 404(a) of Regulation S-K exist with the director.

• ·Appointment includes joinder to letter agreement dated February 27, 2025 (amended November 14, 2025) and indemnification agreement similar to those of existing officers/directors.
• ·Company is a Cayman Islands exempted company, emerging growth company, listed on Nasdaq (LOKVU, LOKV, LOKVW).

02-03-2026

Semrush reported Q4 2025 revenue of $117.7M, up 15% YoY, and full-year revenue of $443.6M, up 18% YoY, with ARR reaching $471.4M (+15% YoY) driven by AI Products ARR surpassing $38M (+850% implied YoY) and Enterprise platform ARR at $37M across 579 customers (+311% YoY). However, GAAP loss from operations widened to $(13.9)M in Q4 (vs prior profit of $1.7M) and $(22.8)M for the full year (vs $8.3M profit), reflecting higher operating expenses. Non-GAAP operating income improved to $15.0M in Q4 (12.8% margin) and $53.3M full year (12% margin), while cash flow from operations was strong at $14.9M Q4 and $59.6M full year; the pending Adobe acquisition is expected to close in H1 2026.

• ·No earnings call or guidance for Q1/FY 2026 due to pending Adobe acquisition.
• ·Acquisition announced November 2025; HSR waiting period expired January 2026; stockholder approval in February 2026; expected close H1 2026.

02-03-2026

Senseonics Holdings, Inc. reported strong Q4 2025 revenue of $14.3 million, up 72% YoY from $8.3 million, and full-year 2025 revenue of $35.3 million, up 57% YoY from $22.5 million, driven by 103% U.S. new patient growth and DTC marketing. However, Q4 net loss widened to $20.8 million from $15.5 million due to SG&A expenses surging to $19.8 million (up $10.9 million YoY), while full-year net loss narrowed to $69.1 million from $78.6 million; outside U.S. revenue remained nearly flat at $2.2 million in Q4 and $7.4 million for the year.

• ·Gross profit FY 2025: $15.8M vs $0.5M in 2024 (significant improvement due to product transition and margins)
• ·SG&A expenses FY 2025: $52.5M, up $18.3M YoY due to DTC investments and commercialization takeover
• ·FY 2026 revenue outlook: $58-62M (+65-76% YoY growth), gross margins ~50%
• ·Gemini pivotal trial first patients enrolled; expected completion H2 2026
• ·Commercialization and distribution of Eversense taken back from Ascensia effective Jan 1, 2026

02-03-2026

William J. Renick resigned as a member of the Tennessee Valley Authority Board of Directors on February 24, 2026. Effective March 2, 2026, Jeremy P. Fisher departed from his role as TVA’s Executive Vice President and Chief Business Officer. No information on successors or reasons for departures was provided.

• ·Filing signed by Thomas C. Rice on March 2, 2026

02-03-2026

Acrivon Therapeutics, Inc. mutually terminated its OncoSignature Companion Diagnostic Agreement with Akoya Biosciences (a Quanterix subsidiary), dated June 17, 2022, effective February 25, 2026, with no financial payments exchanged. The termination enables transition of ACR-368 OncoSignature testing to Acrivon's newly certified in-house CLIA laboratory, completed February 18, 2026, providing full control over development, biomarkers, and commercialization rights. Quanterix will support ongoing clinical testing needs during the transition for Acrivon's registrational-intent Phase 2b study.

• ·Termination involves transfer of all procedures, materials, and know-how from Akoya to Acrivon
• ·Supports streamlining of co-regulatory approvals and co-commercialization of therapeutics and diagnostics

02-03-2026

Vista Gold Corp. announced a proposed underwritten public offering of US$30.0 million in common shares, with a 30-day underwriter option for up to an additional US$4.5 million to cover over-allotments, led by CIBC Capital Markets. Net proceeds are intended for exploration and development at the Mt. Todd gold project in Australia and general corporate purposes. The offering is subject to market conditions, TSX approval, and other factors, with no assurance of completion or final terms.

• ·Shelf registration on Form S-3 (No. 333-282706) filed October 17, 2024, effective November 8, 2024.
• ·Offering also in Canadian provinces except Quebec under listed issuer financing exemption.
• ·Closing subject to TSX approval under Section 602.1 exemption.

02-03-2026

Brinker International, Inc. (NYSE: EAT) promoted George Felix to Executive Vice President, Chief Marketing Officer, overseeing marketing for both Chili’s Grill & Bar and Maggiano’s Little Italy, effective March 2, 2026. Felix, who joined in 2022 as SVP and CMO of Chili’s, contributed to the company's market capitalization growing from $1.3B to $6.25B during his tenure. No declines or flat metrics were reported in the announcement.

• ·Brinker operates in 31 countries and two U.S. territories.
• ·Felix received awards including Fast Company’s 2025 CMOs of the Year, Ad Age 2025 CMO of the Year, and ADWEEK 2024 Marketing Vanguard.

02-03-2026

Wesbanco, Inc. filed an 8-K on March 2, 2026, providing updated unaudited pro forma condensed combined statement of income for the year ended December 31, 2025, supplementing prior disclosures related to its acquisition of Premier Financial Corp., completed on February 28, 2025. This update supersedes or supplements information from prior 8-K filings dated March 28, 2025, and September 10, 2025. No specific financial metrics or performance changes are detailed in the filing body.

• ·Acquisition of Premier Financial Corp. completed on February 28, 2025.
• ·Pro forma statement covers year ended December 31, 2025.
• ·Updates prior reports filed on March 28, 2025, and September 10, 2025.

02-03-2026

Mid Penn Bancorp, Inc. (NASDAQ: MPB) completed its acquisition of 1st Colonial Bancorp, Inc. on February 27, 2026, in a cash-and-stock transaction valued at approximately $106.1 million, merging 1st Colonial Community Bank into Mid Penn Bank and expanding its footprint into the greater Philadelphia area and southern New Jersey. The combined company now has approximately $7 billion in consolidated assets and 62 retail locations. Thomas R. Brugger, former director of 1st Colonial, was appointed as a director of Mid Penn and Mid Penn Bank.

• ·Acquisition completed after close of business on February 27, 2026; filing dated March 2, 2026
• ·Keefe, Bruyette & Woods served as exclusive financial advisor to Mid Penn; Stephens Inc. to 1st Colonial

02-03-2026

Ivanhoe Electric Inc.'s majority-owned subsidiary, Cordoba Minerals Corp., announced that shareholders of JCHX Mining Management Co., Ltd. approved a Waiver and Amending Agreement amending the terms of the sale of Cordoba’s remaining 50% interest in the Alacrán Project, all other exploration assets in Colombia, and certain accounts receivable. The transaction is scheduled to close on March 6, 2026. No financial terms or impacts were disclosed.

• ·Filing date: March 2, 2026
• ·Transaction originally announced previously (details not specified)

02-03-2026

FB Bancorp, Inc. (NASDAQ: FBLA)'s subsidiary, Fidelity Bank, completed the sale of certain assets of its NOLA mortgage division to First Federal Bank on March 1, 2026, pursuant to an Asset Purchase Agreement dated December 31, 2025. The transaction was previously disclosed, and no financial terms or impacts were detailed in the filing.

• ·Asset Purchase Agreement dated December 31, 2025
• ·Fidelity Bank located in New Orleans, Louisiana
• ·First Federal Bank located in Lake City, Florida

02-03-2026

Resolute Holdings Management, Inc. converted from a Delaware corporation to a Nevada corporation and adopted new Articles of Incorporation effective upon filing. The new articles authorize 1,100,000,000 total shares (1,000,000,000 Common Stock and 100,000,000 Preferred Stock, both with $0.0001 par value), establish a classified board of up to 12 directors divided into three classes, and include provisions limiting stockholder actions by written consent and special protections tied to 'Investor' ownership exceeding 40% of voting power. No financial performance metrics or period-over-period changes are reported.

• ·Filing Date: March 02, 2026
• ·No cumulative voting for Common Stock
• ·Directors may only be removed for cause by 2/3 vote of voting power
• ·Board authorized to fill vacancies without stockholder vote
• ·No preemptive or subscription rights for Common Stock holders
• ·Trigger Date occurs when Investors cease to beneficially own 40% of voting power

02-03-2026

BGSF, Inc. appointed Keith Schroeder and Kelly Brown as permanent Co-Chief Executive Officers. On February 24, 2026, subsidiary B G Staff Services, Inc. entered into an Executive Employment Agreement with Ms. Brown, providing an initial annualized base salary of $375,000 through December 31, 2027, with eligibility for EBITDA-based annual bonuses, 1% acquisition bonuses, discretionary incentives, and severance of 12 months base salary (18 months post-change of control). Additional agreements include non-disclosure, non-compete (12 months), non-solicitation (18 months), and indemnification.

• ·Severance includes COBRA premiums for 18 months upon qualifying termination.
• ·Full vesting of equity awards upon qualifying termination.
• ·Non-compete restricted for 12 months post-termination; non-solicitation and non-interference for 18 months.
• ·Prior disclosure incorporated from 8-K filed June 23, 2025.

02-03-2026

Keen Vision Acquisition Corp. entered into a binding Letter of Intent (LOI) on February 26, 2026, with Medera Inc. and its wholly-owned subsidiary Novoheart Group Limited (NVH) to negotiate and execute a replacement merger agreement by April 10, 2026, following the termination of a prior merger agreement dated September 3, 2024, due to volatility and cautious sentiment in the US biotechnology sector. The LOI sets NVH's enterprise valuation at $100M and requires at least $10M in available liquidity at closing after capping transaction expenses at $0.7M for Parent and $1.3M for NVH, with the deal structure to be optimized for tax efficiency. However, the prior agreement's termination highlights ongoing market challenges, and the LOI will terminate if no replacement is signed by the deadline.

• ·Prior Merger Agreement dated September 3, 2024, terminated concurrently with LOI execution via mutual release.
• ·PIPE fundraising, if pursued, must close within 9 months of LOI signing; Replacement Merger Agreement terminates if closing conditions not met within 9 months of LOI.
• ·Promissory notes to KVC Sponsor LLC subject to mutually agreed maximum cap (Note Cap) to be detailed in Replacement Merger Agreement.
• ·NVH currently has no external liabilities; internal liabilities to be converted to equity prior to closing.
• ·Medera China Company Limited and subsidiaries excluded from business combination.

02-03-2026

TriplePoint Venture Growth BDC Corp. entered into a Master Note Purchase Agreement dated February 27, 2026, authorizing the issuance and sale of $75M aggregate principal amount of 7.50% Series 2026 Senior Notes due February 27, 2028. The notes include provisions for interest rate adjustments upward by 1.00% upon a Below Investment Grade Event or Secured Debt Ratio Event, providing flexibility but potential cost increases for the company.

• ·Agreement filed as Exhibit 10.1 in 8-K on March 02, 2026.
• ·SEC filing items: 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 9.01 (Financial Statements and Exhibits).
• ·Below Investment Grade Event defined based on ratings from NRSROs; company required to maintain at least one Investment Grade rating per Section 9.8.
• ·Secured Debt Ratio calculated excluding SBIC Subsidiaries, with pro forma adjustments for projected cash from asset sales, equity, or unsecured debt within 60 days.

02-03-2026

Bausch Health Companies Inc. announced on February 26, 2026, amendments to 2023 performance share unit (PSU) award agreements for named executive officers Thomas Appio (1,137,862 PSUs) and Seana Carson (137,922 PSUs), changing settlement from stock to cash equal to the market price of common stock on the March 3, 2026 vesting date. The Talent and Compensation Committee approved the amended Appio Agreement, while the Carson Agreement involves her irrevocable disposition of PSUs under Canadian tax rules. Full agreements will be filed in the upcoming Form 10-Q for the quarter ending March 31, 2026.

• ·2023 PSUs originally granted in March 2023 and earned over a three-year performance period.
• ·Appio Agreement amended and restated by the Talent and Compensation Committee.
• ·Carson Agreement authorized under paragraph 7(1)(b) of the Income Tax Act (Canada).

02-03-2026

Intuitive Surgical, Inc. completed its acquisition of the da Vinci and Ion distribution business operated by ab medica, Abex, Excelencia Robótica, and their affiliates on March 1, 2026. The company issued a press release on March 2, 2026, announcing the transaction, with the press release furnished as Exhibit 99.1. No financial terms, performance metrics, or other quantitative details were disclosed in the filing.

• ·Acquisition closed on March 1, 2026; press release dated March 2, 2026

02-03-2026

Fortress Value Acquisition Corp. V, a blank check company sponsored by an affiliate of Fortress Investment Group LLC, announced the pricing of its $250M initial public offering of 25,000,000 Class A ordinary shares at $10.00 per share, with trading on Nasdaq under ticker FVAV beginning February 26, 2026. Deutsche Bank Securities Inc. serves as the sole underwriter, with a 45-day option to purchase up to an additional 3,750,000 shares for over-allotments. The registration statement was declared effective by the SEC on February 25, 2026.

• ·SEC registration statement declared effective on February 25, 2026.
• ·45-day underwriter option to cover over-allotments.

02-03-2026

Banner Corporation (NASDAQ: BANR) appointed Monica O’Reilly and Judith Steiner to its Board of Directors effective March 1, 2026, with both also joining the Banner Bank board. O’Reilly, with over 30 years in financial services including as Vice Chairman at Deloitte, will serve on the Corporate Governance/Nominating and Risk Committees; Steiner, former Banner Bank Chief Risk Officer (2016-2021), will serve on the Credit Risk and Risk Committees. CEO Mark Grescovich highlighted their expertise in compliance, risk, cybersecurity, and AI as key to strengthening the board for long-term growth.

• ·O’Reilly recognized as one of the 'Most Influential Women in Business' by San Francisco Business Journal (2021); holds B.A. from Queen’s University Belfast and Wharton Executive Leadership Program.
• ·Steiner holds Juris Doctor from Case Western Reserve University and B.A. from University of Akron; prior roles at FirstMerit included General Counsel and Secretary.